Mobachir El Kettani,Kashish Shah,Hareem Farooq et al.
Mobachir El Kettani et al.
This case report explains an extraordinary presentation of chronic myeloid leukemia (CML) in a 39-year-old male with a T315I mutation, presenting with acute bilateral hearing loss and imbalance secondary to myeloid blast crisis. Neurologica...
Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in Jehovah's witness patients [0.03%]
Jehovah见证人患者的费城染色体阳性急性淋巴细胞白血病的治疗
Jeffrey Baron,Manu R Pandey,Elizabeth A Griffiths et al.
Jeffrey Baron et al.
Avatrombopag for severe refractory thrombocytopenia in a pediatric patient with ALL following allogeneic hematopoietic stem cell transplantation: A case report [0.03%]
接受异基因造血干细胞移植后患急性淋巴细胞白血病患儿严重难治性血小板减少使用艾曲波帕治疗的病例报告
Emilie J Lynch,Autumn Citta,Constance Alford et al.
Emilie J Lynch et al.
Patients who receive allogeneic hematopoietic stem cell transplantation (alloHSCT) are at risk for developing persistent thrombocytopenia. Here, we describe treatment with avatrombopag, a thrombopoietin receptor agonist, in a pediatric pati...
Olaparib induced aplastic anemia in a patient with castrate resistant prostate cancer: A case report [0.03%]
奥拉帕尼致去势抵抗性前列腺癌患者再生障碍性贫血1例报告
Elrazi A Ali,Monika Jain,Akriti Pokhrel et al.
Elrazi A Ali et al.
Olaparib is (ADP-ribose) polymerase inhibitor (PARPi), which stops the repair of single-stranded DNA breaks. This leads to the death of cancer cells with BRCA1/BRCA2 mutations or homologous recombination deficiency. Since being approved by ...
Micro-transplantation in an elderly patient with very high risk MDS:A case report and literature review [0.03%]
高危骨髓增生异常综合征老年患者微移植治疗1例及文献回顾
Kangli Wu,Mingsuo Liu,Yajun Wu et al.
Kangli Wu et al.
Introduction: The prognosis of patients with myelodysplastic syndromes (MDS) (very high risk) is poor.HLA-mismatched allogeneic T-cell infusion which is called micro-transplantation can not only shorten the time of bone m...
Management of patients with concurrent clonal plasma cell and myeloid disorders: A single center descriptive case series [0.03%]
共克隆浆细胞病和髓系肿瘤患者的治疗：单一中心描述性病例系列分析
Michael J Hochman,Gloria F Gerber,Philip H Imus et al.
Michael J Hochman et al.
Both clonal plasma cell and myeloid disorders occur more frequently with age. Patients with concurrent clonal plasma cell and myeloid disorders (CPCMD) can present clinical and therapeutic challenges. In this single-institution cohort of pa...
A 95-year-old patient suffered high-grade B-cell lymphoma combined hairy cell leukemia [0.03%]
一名95岁高龄患者患高等级B细胞淋巴瘤合并毛细胞白血病
Lingli Wang,Jing Wang,Min Li et al.
Lingli Wang et al.
This case report discusses a 95-year-old man diagnosed with two types of lymphomas. He was hospitalized for erysipelas in September 2018. The lymph node revealed high-grade B-cell lymphoma with Myc and Bcl-2 rearrangement. Bone marrow biops...
Real-world treatments and clinical outcomes in unfit AML patients receiving first-line treatment or best supportive care in Italy (CURRENT study) [0.03%]
意大利不适用强化疗的急性髓系白血病患者的真实世界治疗及临床转归（CURRENT研究）
Maria Paola Martelli,Nicola Di Renzo,Antonio Curti et al.
Maria Paola Martelli et al.
Real-world data on treatment patterns and outcomes of patients with acute myeloid leukemia unfit for intensive chemotherapy are lacking before the advent of precision medicine in this setting. Herein, we present the Italian sub-analysis of ...
BCR-ABL kinase domain mutations in CML patients, experience from a tertiary care center in North India [0.03%]
印度北部三级医疗中心慢性髓性白血病患者的BCR-ABL激酶结构域突变情况
Akhilesh S,Arunim Shah,Ashish Ashish et al.
Akhilesh S et al.
Background: Chronic Myeloid Leukemia is characterized by the presence of the Philadelphia Chromosome (Ph) which contains the BCR::ABL1 fusion gene that occurs due to a reciprocal translocation between chromosomes 9 and 22...
A tertiary care centre experience with Elranatamab: A report of three cases [0.03%]
Elranatamab的三级护理中心经验报告：三例报道
Disha Kakkar,Aakanksha Singh,Reshmi Harikumar Pillai et al.
Disha Kakkar et al.
Introduction: The introduction of proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies has changed the treatment paradigm of multiple myeloma. With the advent of these new therapeutic options, life exp...